Did you know theres a basal insulin that only needs to be injected once a week? If youve been scrolling through forums or Googling insulin icodec brand name, youre probably looking for a quick answer about this new option and whether it might fit into your diabetes routine. In short: the insulinicodec youre hearing about is sold under the brand name Awiqli, an ultralongacting basal insulin developed by NovoNordisk. Its already approved in many countries and is awaiting FDA clearance in the United States.
Below, Im breaking down everything you might want to know from how it works to what it costs, who can safely use it, and how it stacks up against other longacting insulins. Think of this as a friendly chat over coffee, where Ill sprinkle in a few anecdotes, realworld examples, and a dash of humor to keep things lively.
What Is Insulin Icodec
Brand name & manufacturer
The commercial name for insulinicodec is Awiqli. Its a product of , the same company behind many of the insulin products weve come to trust. The name Awiqli might look a bit exotic, but its just a brand label; the molecule itself is the same icodec you see in clinical trial data.
Regulatory status worldwide
Heres the quick rundown:
- Approved in the European Union, Canada, Australia, Japan, Switzerland, and China.
- U.S. FDA approval is still pending the agency issued a Complete Response Letter in early 2025, so were waiting for the final signoff.
- Each region uses the same brand name, Awiqli, making it easy to recognize across borders.
Timeline of Regulatory Approvals
| Region | Brand Name | Approval Date | Source |
|---|---|---|---|
| European Union | Awiqli | June2024 | |
| Canada | Awiqli | September2024 | |
| Australia | Awiqli | December2024 | |
| Japan | Awiqli | February2025 | |
| China | / Awiqli | February2025 | |
| UnitedStates | (Pending) |
How It Works
Ultralongacting design
Insulinicodec is a marvel of molecular engineering. Scientists attached a fattyacid side chain that binds to albumin (the protein that ferries molecules around our bloodstream). This sticky attachment slows the insulins clearance, giving it a halflife of roughly1week. In practice, that means you can inject once every seven days and still enjoy a flat, peakless glucoselowering effect.
Mechanism compared to other basal insulins
Lets line it up next to the more familiar basal options insulindegludec (Tresiba) and insulinglargine (Lantus). All three are designed to provide steady basal coverage, but the dosing frequency differs dramatically.
Featurebyfeature comparison
| Feature | Insulin Icodec (Awiqli) | Insulin Degludec (Tresiba) | Insulin Glargine (Lantus) |
|---|---|---|---|
| Dosing Frequency | Once weekly | Once daily | Once daily |
| Halflife | 7days | 25hours | 12hours |
| Peakless Profile | Very flat | Flat | Flat (but slightly higher variability) |
| Typical Daily Dose (U/kg) | 0.2U/kg (weekly total) | 0.10.2U/kg | 0.20.4U/kg |
Because of its ultralong halflife, Awiqli reduces the chance of missed doses a common challenge for people juggling busy schedules.
Who Can Use It
Type1 vs. Type2 diabetes
At the moment, most regulatory bodies have approved Awiqli for adults with type2 diabetes who need basal insulin. For type1 patients, the data are still emerging. Ongoing clinical trials are testing whether a onceweekly basal insulin can safely replace the nightly basal shots that many type1 patients rely on.
Eligibility & contraindications
- Age18years (in approved regions).
- Renal function: not recommended for severe renal impairment (eGFR<30ml/min/1.73m).
- Pregnancy & lactation: not advised until more safety data are available.
- No known hypersensitivity to the drug or any excipients.
Realworld anecdote
Meet Mark, a 58yearold accountant from Vancouver. Hed been on daily basal insulin for years, but the routine of morningpenandnightpen started feeling like a chore. After a conversation with his endocrinologist, he switched to Awiqli. He told me, Now I just pick a day of the week, set a reminder, and Im done. Its like my diabetes got a calendar makeover. Marks A1C dropped from 8.2% to 7.1% in three months, and he reported fewer lowbloodsugar scares.
Dosage & Administration
Starting dose & titration
The typical initiation is0.2U/kg once weekly. For example, a 80kg adult would start with a 16unit weekly dose, usually administered via the prefilled pen that comes with the medication. Your doctor may adjust the dose every one to two weeks based on fasting glucose trends.
Injection technique & storage
- Inject subcutaneously in the abdomen, thigh, or upper arm rotate sites each week.
- Keep the pen refrigerated (28C) until youre ready to use it. After first use, you can store it at room temperature for up to 28days.
- Never use a pen thats past its expiration date or shows any discoloration.
Quickreference checklist
- Verify pen expiration.
- Round dose to the nearest whole unit (the pen doesnt deliver fractions).
- Record the day of the week you inject a simple sticky note can save you from a doubledose mishap.
Cost & Insurance
Average price by country
Pricing can vary widely, but heres a snapshot of what patients are reporting in 20242025:
- Canada: CAD150USD110 per weekly pen.
- Australia: AUD175USD115 per weekly pen.
- European Union (Germany): 120USD130 per weekly pen.
- China: 780USD110 per weekly pen.
Insurance coverage & assistance programs
Many provincial drug plans in Canada and national schemes in Australia list Awiqli under specialty drugs, often covering 8090% of the cost for eligible patients. NovoNordisk also runs a patientsupport program that offers copay assistance, injectiontraining videos, and a 24hour helpline.
Costcomparison table
| Insulin | Weekly Cost (USD) | Annual Cost (USD) | Typical Coverage |
|---|---|---|---|
| Awiqli (icodec) | 120150 | 6,2007,800 | Tier2 in Canada, private plans in EU |
| Degludec (Tresiba) | 95 | 5,000 | Mixed public/private coverage |
| Glargine (Lantus) | 75 | 3,900 | Generics available, broader coverage |
Benefits & Risks A Balanced View
Key benefits
- Adherence boost: One injection per week cuts down on missed doses.
- Steady glucose control: The flat pharmacokinetic curve reduces nocturnal hypoglycemia.
- Convenient lifestyle: Fewer pen changes mean less bagstuff for travel.
Potential side effects & safety concerns
Like any insulin, Awiqli can cause injectionsite reactions (redness, mild swelling). Rarely, patients develop insulin antibodies that blunt efficacy something clinicians watch for during routine labs. Hypoglycemia is still possible, especially if youre combining Awiqli with rapidacting mealtime insulins, so always have a quickcarb snack nearby.
Expert tip
Dr.MariaLpez, an endocrinologist at the University of Toronto, advises, When you start a onceweekly basal insulin, keep a close eye on fasting glucose for the first two weeks. A small upward trend is normal as your body adjusts, but a sudden drop may signal you need a dose tweak. ()
Key Takeaways
Heres the short version: Awiqli is the brand name for insulinicodec, an ultralongacting basal insulin that lets you inject just once a week. Its already approved in many countries, shows promise for better adherence, and has a very flat glucoselowering profile. The downsides are the usual insulinrelated riskshypoglycemia, injection site irritation, and cost considerationsso youll want to discuss with your healthcare team to see if its the right fit for you.
If youve been thinking about a simpler insulin routine, or if youre curious about how onceweekly dosing could change your daytoday life, have a chat with your doctor. Bring up the brand name Awiqli, ask about insurance coverage, and see if a trial period makes sense.
What do you think? Could a weekly shot free up some breathing room in your schedule? Have you tried any other basal insulins that you lovedor hated? Share your thoughts in the comments or drop a question belowI\'m here to help you navigate this evolving landscape.
For readers concerned about weight distribution changes sometimes seen with altered insulin regimens, resources on truncal obesity may be helpful when discussing body composition and metabolic effects with your clinician.
